To assess whether targeting PRMT5 could boost tumor immunity, we first employed the syngeneic MMTV-neu breast tumor model with EPZ004777 treatment, which is has previously been used in a mouse tumor model (32). The gene discussed is ERBB2; the disease is neoplasm.